What baseline and follow‑up blood investigations are recommended for a patient on paliperidone depot 100 mg intramuscularly every 4 weeks and oral olanzapine 5 mg nightly?

Blood Investigations for Paliperidone Depot and Olanzapine Combination Therapy

Before starting this antipsychotic regimen and at regular intervals thereafter, obtain: BMI, waist circumference, blood pressure, HbA1c, fasting glucose, lipid panel, prolactin, liver function tests, urea and electrolytes, full blood count, and electrocardiogram. 1

Baseline Investigations (Before Initiating Treatment)

The following comprehensive metabolic and hematologic panel should be obtained before starting either medication 1:

• Metabolic parameters:

  • BMI and waist circumference 1
  • Blood pressure 1
  • HbA1c 1
  • Fasting glucose (or random glucose if fasting sample cannot be obtained, followed by fasting confirmation if abnormal) 1
  • Complete lipid panel (total cholesterol, triglycerides, HDL, LDL) 1

• Endocrine assessment:

  • Prolactin level (particularly important for paliperidone, which causes significant prolactin elevation) 1, 2

• Organ function:

  • Liver function tests 1
  • Urea and electrolytes (renal function) 1
  • Full blood count 1

• Cardiac assessment:

  • Electrocardiogram 1

Early Follow-Up Monitoring

At 4 weeks after initiation, repeat fasting glucose to detect early metabolic derangement, as both medications carry significant metabolic risk 1. This is particularly critical given olanzapine's high metabolic liability 3, 2.

Weekly for 6 weeks, monitor:

• BMI 1
• Waist circumference 1
• Blood pressure 1

Ongoing Monitoring Schedule

At 3 months (12 weeks), repeat the complete baseline panel 1:

• All metabolic parameters (BMI, waist circumference, blood pressure, HbA1c, fasting glucose, lipids) 1
• Prolactin 1
• Liver function tests 1
• Renal function 1
• Full blood count 1

Annually thereafter, repeat all baseline investigations 1.

Critical Metabolic Considerations for This Specific Combination

This combination carries particularly high metabolic risk because olanzapine has one of the worst cardiometabolic profiles among antipsychotics 1, 3. Evidence demonstrates:

• Olanzapine significantly worsens the triglyceride/HDL ratio (a marker of insulin resistance), with mean increases of 0.97 at 6 months, while paliperidone shows no significant change 3

• Insulin resistance (HOMA-IR) worsens significantly with olanzapine but not with paliperidone 3

• Weight gain is significantly greater with olanzapine (3.8 kg) compared to paliperidone (1.2 kg) over 6 months 3

• New-onset metabolic syndrome and triglyceride abnormalities are more common with olanzapine 3

• Both medications increase prolactin, but paliperidone causes significantly higher elevations than olanzapine at all time points 2

Additional Monitoring Considerations

For prolactin monitoring: Given paliperidone's potent prolactin elevation 2, counsel patients on risks of untreated hyperprolactinaemia including reduced bone mineral density and increased breast cancer risk in women 1. Monitor for symptomatic hyperprolactinaemia (galactorrhea, sexual dysfunction, menstrual irregularities).

For renal function: This is particularly important before considering metformin augmentation (which should be offered when starting olanzapine given its poor cardiometabolic profile), as metformin should be avoided in renal failure 1.

Therapeutic drug monitoring: While not routinely required, paliperidone serum concentrations can be measured if adherence is questioned or response is suboptimal 4. The suggested therapeutic range is 20-60 ng/mL (47-140 nmol/L) 4. For olanzapine, therapeutic levels are typically >23.2 ng/mL at 12 hours post-dose 5.

Common Pitfalls to Avoid

• Do not skip the 4-week fasting glucose check – early metabolic changes are common and require prompt intervention 1
• Do not rely on random glucose alone – if abnormal, obtain fasting confirmation 1
• Do not neglect prolactin monitoring – paliperidone causes marked elevation that may require intervention 2
• Do not forget annual monitoring – metabolic effects can develop or worsen over time even after initial stability 1